⦁《Dermatology and Therapy》is a leading peer-reviewed international journal published by the Springer Verlag.

⦁  760 kDa botulinum toxin achieved visible wrinkle reduction by Day 3, peaked at Week 4, with >60% maintaining improvement and satisfaction at Month 6.

⦁  The study results will be presented at the Taiwan Dermatology Association and Taiwan Society of Plastic Surgery Societies Annual Meetings in November and December.

Taipei, Taiwan – November 4, 2025 – OBIGEN Pharma Inc. (hereinafter referred to as “the Company”) is pleased to announce that the results of its Phase II clinical trial for its proprietary 760 kDa botulinum toxin have been published on November 1, 2025, in Dermatology and Therapy, a leading peer-review international dermatology journal under Springer Verlag. This milestone highlights the global recognition of Taiwan’s first botulinum toxin developed from a native strain.

The multicenter, randomized, double-blind, placebo-controlled Phase II study evaluated the efficacy, safety, and optimal dosing of OBIGEN’s novel botulinum toxin in participants with moderate to severe glabellar lines. The findings demonstrated that a 20U dose produced visible wrinkle reduction as early as Day 3 post-injection, with peak improvement observed at Week 4. The therapeutic effect remained durable, with over 60% of participants self-assessed maintaining visible improvement and satisfaction at Month 6.

The product exhibited a good safety profile, with no treatment-related serious adverse events or antibody formation. These results underscore the product’s potential for rapid onset, long-lasting efficacy, and good tolerability. The 20U dose has been selected as the optimal clinical dose for subsequent development.

OBIGEN Pharma will present these pivotal findings at two major academic conferences:

•     Taiwan Dermatological Association Annual Meeting on November 7, 2025

•     Taiwan Society of Plastic Surgery Annual Meeting on December 13, 2025

 

Patricia Chou, CEO of OBIGEN Pharma, stated:
“The publication of our Phase II clinical trial results in a prestigious international journal, along with upcoming presentations at key medical conferences, brings global visibility and recognition to Taiwan’s first botulinum toxin developed from a native strain. We are confident as we prepare to initiate our Phase III trial in Taiwan by year-end and submit our U.S. Phase II trial application (IND) in early 2026.”

OBIGEN Pharma remains committed to advancing its clinical development programs in Taiwan and the United States, with the goal of delivering innovative therapeutic solutions to patients worldwide and creating long-term investment value.

About OBIGEN Pharma
OBIGEN Pharma Inc. is Taiwan’s only integrated pharmaceutical company dedicated to the development and production of the novel 760 kDa botulinum toxin. With proprietary strains, advanced formulations, and cutting-edge manufacturing processes, the Company delivers high-quality, differentiated botulinum toxin products for both aesthetic and therapeutic applications—empowering people to pursue health and beauty in harmony.